Perrigo sets production records; Sanofi's Viehbacher pleased with Irish plant;

> Despite adding processes and procedures to improve quality, which slowed manufacturing throughput, Perrigo ($PRGO) CEO Joseph Papa said in a conference call that the drugmaker has "set production records over the past few months." Transcript

> "We are extremely happy with how the facility is performing," says Sanofi ($SNY) CEO Chris Viehbacher (photo) regarding the newly expanded former Genzyme plant in Waterford, Ireland. Story

> Indian bulk drugs maker Parabolic said it has received official accreditation from Japan's ministry of health to supply the antibiotic cephalosporin in that country. Story

> Use of plastic containers for drug products complicates choice of label material--components in inks, lacquers, top coats, adhesives, paper and film can leach through the container wall, contaminating medicine. Story

> Contract manufacturer CoreRx has added an Xcelodose precision powder micro-dosing system to its product development arsenal, citing client requirements for preclinical and early phase clinical GMP supply. Announcement

> Pharmetics/Jarvis Pharma and the Town of Fort Erie, Ontario, Canada, are paying consultancy Deloitte $100,000 to assess the viability and options of a manufacturing plant there. Story

> A $313 million investment by respiratory drugmaker Nephron Pharmaceuticals will open up 707 jobs in Lexington County, SC.  Story

> A group of public interest organizations from across the globe want the World Health Organization to disassociate from the International Medical Products Anti-Counterfeiting Taskforce and stop using the word "counterfeit" to refer to medical products of compromised quality, safety and efficacy. Story

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)